No Data
No Data
No Data
No Data
No Data
Shanghai Yizhong Pharmaceutical Co., Ltd.'s (SHSE:688091) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Shanghai Yizhong Pharmaceutical (SHSE:688091) has had a rough three months with its share price down 34%. However, a closer look at its sound financials might cause you to think again. Given that fu
Simply Wall StApr 12 20:42 ET
Shanghai Yizhong Pharmaceutical (SHSE:688091) Seems To Use Debt Rather Sparingly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' So it seems
Simply Wall StMar 5 20:17 ET
Shanghai Yizhong (688091.SH) Performance Report: Net profit of 2023 was 163 million yuan, up 13.78% year-on-year
Gelonghui, Feb. 26: Shanghai Yizhong (688091.SH) announced the 2023 Annual Results Report. The company achieved operating revenue of 360 million yuan in 2023, an increase of 52.68% over the previous year. Net profit attributable to owners of the parent company was 163 million yuan, up 13.78% from the previous year; net profit attributable to owners of the parent company after deducting non-recurring profit and loss was 162 million yuan, an increase of 57.66% over the previous year.
Gelonghui FinanceFeb 26 04:57 ET
Yizhong Pharmaceutical Starts Construction of Paclitaxel Polymer Micelles Production Facility; Shares Down 3%
Shanghai Yizhong Pharmaceutical (SHA:688091) started building a facility producing paclitaxel polymer micelles for injection after obtaining a construction license from the local government of China's
MT NewswiresFeb 5 01:38 ET
Shanghai Yizhong (688091.SH): “Construction of 5 million injectable paclitaxel polymer micelles and supporting facilities per year” has obtained a construction license for construction projects
Gelonghui, Feb. 4: Shanghai Yizhong (688091.SH) announced that it has recently obtained a “Construction Permit” issued by the Fengxian District Construction and Management Committee, marking that the “construction of 5 million injectable paclitaxel polymer micelles and supporting facilities per year” has entered the construction phase.
Gelonghui FinanceFeb 4 02:39 ET
Shanghai Yizhong Pharmaceutical Co., Ltd.'s (SHSE:688091) Stock Price Dropped 11% Last Week; Individual Investors Would Not Be Happy
Key Insights Shanghai Yizhong Pharmaceutical's significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public The top 7 shareholders
Simply Wall StJan 28 21:29 ET
No Data
No Data